Payment overview · 2025
General Payments
$236.74
12 reported records · 8 companies
Healthcare provider profile · identity verified
Gregory L Runser, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GROVE CITY, OH · NPI 1750320347
Verified facts
What the public records show
CMS Open Payments records show Gregory L Runser, M.D. received $236.74 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 37.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.61 | 37.4% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $31.15 | 13.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.10 | 10.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.43 | 9.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.76 | 8.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.37 | 7.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.72 | 6.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.60 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $236.74 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.74 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.87 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.87 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $31.15 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 934 | 255 |
| Amlodipine Besylate | Amlodipine Besylate | 573 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 497 | 138 |
| Lisinopril | Lisinopril | 482 | 137 |
| Omeprazole | Omeprazole | 421 | 115 |
| Metoprolol Succinate | Metoprolol Succinate | 318 | 97 |
| Metformin Hcl | Metformin Hcl | 293 | 95 |
| Gabapentin | Gabapentin | 291 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 283 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 254 | 76 |
| Eliquis | Apixaban | 243 | 53 |
| Glimepiride | Glimepiride | 229 | 69 |
| Simvastatin | Simvastatin | 216 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 212 | 65 |
| Valsartan | Valsartan | 194 | 56 |
| Prednisone | Prednisone | 193 | 158 |
| Potassium Chloride | Potassium Chloride | 180 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 175 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 169 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 162 | 50 |
| Losartan Potassium | Losartan Potassium | 162 | 55 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 154 | 43 |
| Sertraline Hcl | Sertraline Hcl | 148 | 44 |
| Tramadol Hcl | Tramadol Hcl | 147 | 33 |
| Carvedilol | Carvedilol | 145 | 39 |
| Furosemide | Furosemide | 139 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 121 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 121 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 28 |
| Klor-Con M20 | Potassium Chloride | 113 | 43 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 111 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 20 |
| Atenolol | Atenolol | 95 | 26 |
| Trazodone Hcl | Trazodone Hcl | 94 | 29 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 89 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 33 |
| Allopurinol | Allopurinol | 88 | 25 |
| Buspirone Hcl | Buspirone Hcl | 88 | 21 |
| Alprazolam | Alprazolam | 86 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 86 | 23 |
| Xarelto | Rivaroxaban | 84 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 15 |
| Pregabalin | Pregabalin | 78 | 15 |
| Metformin Hcl Er | Metformin Hcl | 72 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 24 |
| Lorazepam | Lorazepam | 65 | 12 |
| Celecoxib | Celecoxib | 63 | 18 |
| Finasteride | Finasteride | 62 | 19 |
| Montelukast Sodium | Montelukast Sodium | 58 | 20 |
| Warfarin Sodium | Warfarin Sodium | 58 | 15 |
| Bupropion Xl | Bupropion Hcl | 54 | 19 |
| Jardiance | Empagliflozin | 53 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 13 |
| Ozempic | Semaglutide | 45 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 15 |
| Glipizide Er | Glipizide | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 38 |
| Mirtazapine | Mirtazapine | 41 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | 11 |
| Chlorthalidone | Chlorthalidone | 39 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 29 |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Ezetimibe | Ezetimibe | 37 | 12 |
| Glipizide | Glipizide | 36 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 14 |
| Spironolactone | Spironolactone | 35 | 12 |
| Famotidine | Famotidine | 34 | 13 |
| Alendronate Sodium | Alendronate Sodium | 33 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 14 |
| Betamethasone Valerate | Betamethasone Valerate | 30 | 14 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Nabumetone | Nabumetone | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Cephalexin | Cephalexin | 23 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Ibu | Ibuprofen | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 14 |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 11 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Ramipril | Ramipril | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $236.74 · 12 records | ABBVIE INC. | AIRSUPRA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ENFLONSIA, FREESTYLE LIBRE 3, GARDASIL 9, M-M-R II, Ozempic, QULIPTA, UBRELVY, VAXNEUVANCE, VRAYLAR, Veozah | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error